About
Technology
Issues
FAQ
Links
Official Page
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.